ENTO
Income statement / Annual
Last year (2023), Entero Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2023, Entero Therapeutics, Inc.'s net income was -$15.79 M.
See Entero Therapeutics, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Cost of Revenue |
$29,274.00 |
$106,207.00 |
$537,400.00 |
$571,145.00 |
$976,982.00 |
$798,446.00 |
$753,998.00 |
$734,500.00 |
$0.00 |
$0.00 |
| Gross Profit |
-$29,274.00 |
-$106,207.00 |
-$537,400.00 |
-$571,145.00 |
-$976,982.00 |
-$798,446.00 |
-$753,998.00 |
-$734,500.00 |
$0.00 |
$0.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Research and Development
Expenses |
$5.03 M
|
$691,257.00
|
$38.32 M
|
$19.14 M
|
$8,680.67
|
$5,771.41
|
$2,395.48
|
$2,496.11
|
$1,398.06
|
$1,050.62
|
| General & Administrative
Expenses |
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6,063.08
|
$7,450.37
|
$7,685.71
|
$4,129.05
|
$3,330.75
|
$1,865.69
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.74 M
|
$11.99 M
|
$18.38 M
|
$7.29 M
|
$6,063.08
|
$7,450.37
|
$7,685.71
|
$4,129.05
|
$3,330.75
|
$1,865.69
|
| Other Expenses |
$0.00 |
-$232,741.00 |
$529,101.00 |
$211,430.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$15.74 M |
$12.68 M |
$56.70 M |
$26.43 M |
$14,743.00 |
$13,431.00 |
$10,221.00 |
$8,654.18 |
$4,342.70 |
$2,884.21 |
| Cost And Expenses |
$15.77 M |
$12.68 M |
$56.70 M |
$26.43 M |
$14,743.00 |
$13,431.00 |
$10,221.00 |
$8,654.18 |
$4,342.70 |
$2,884.21 |
| Interest Income |
$2,531.00 |
$8,415.00 |
$1,173.00 |
$484.00 |
$0.00 |
$101.85 |
$875.20 |
$5,937.49 |
$1,587.53 |
$68.15 |
| Interest Expense |
$22,463.00 |
$15,879.00 |
$11,235.00 |
$5.84 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Depreciation &
Amortization |
$29,274.00
|
$29,271.00
|
$542,255.00
|
$565,345.00
|
$635.05
|
$798.45
|
$754.00
|
$734.50
|
$733.60
|
$434.09
|
| EBITDA |
-$15.74 M
|
-$14.51 M
|
-$57.99 M
|
-$26.26 M
|
-$13.77 M
|
-$12.63 M
|
-$9.47 M
|
-$7.92 M
|
-$3.61 M
|
-$1.87 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other
Income/Expenses Net |
-$24,156.00
|
-$1.95 M
|
-$1.83 M
|
-$6.24 M
|
-$433,939.00
|
-$311,846.00
|
-$1.02 M
|
-$7.97 M
|
-$1.20 M
|
$551,164.00
|
| Income Before Tax |
-$15.79 M |
-$14.63 M |
-$58.54 M |
-$32.67 M |
-$15,177.69 |
-$13,533.62 |
-$11,096.38 |
-$14,591.66 |
-$5,930.24 |
-$2,952.35 |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00 |
$126,565.00 |
$26.52 M |
$15.11 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
-$587.21 |
| Net Income |
-$15.79 M |
-$14.63 M |
-$58.54 M |
-$32.67 M |
-$15.18 M |
-$13.53 M |
-$11.10 M |
-$14.59 M |
-$5.93 M |
-$2.37 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
| EPS |
-47.88 |
-416.9326 |
-39770 |
-61637 |
-28425 |
-36815 |
-43680 |
-94080 |
-25480 |
-10162 |
| EPS Diluted |
-47.88 |
-416.9326 |
-39770 |
-61637 |
-28425 |
-36815 |
-43680 |
-94080 |
-25480 |
-10162 |
| Weighted Average Shares
Out |
$336,342.00
|
$35,912.00
|
$2,125.17
|
$677.05
|
$533.94
|
$367.60
|
$253.07
|
$154.88
|
$232.74
|
$232.74
|
| Weighted Average Shares
Out Diluted |
$336,342.00
|
$35,912.00
|
$2,125.17
|
$677.05
|
$533.94
|
$367.60
|
$253.07
|
$154.88
|
$232.74
|
$232.74
|
| Link |
|
|
|
|
|
|
|
|
|
|
